Women's Clinic, Ghent University Hospital (Drs. Wessel, Rombaut, Vanhulle, Hamerklynck, Weyers), Ghent, Belgium.
Women's Clinic, Ghent University Hospital (Drs. Wessel, Rombaut, Vanhulle, Hamerklynck, Weyers), Ghent, Belgium.
J Minim Invasive Gynecol. 2023 Jun;30(6):473-479. doi: 10.1016/j.jmig.2023.02.010. Epub 2023 Feb 16.
To compare nifedipine, naproxen, or placebo for pain relief during diagnostic hysteroscopy.
Double-blind, randomized controlled pilot study.
University hospital.
Women scheduled for office diagnostic hysteroscopy (n = 60).
Women received nifedipine (2 tablets of 10 mg), naproxen (2 tablets of 250 mg), or placebo (2 tablets of 500 mg lactose) 30 to 60 minutes prior to hysteroscopy.
Sixty patients were enrolled in the study (21 in the nifedipine group, 19 in the naproxen group, and 20 in the placebo group). The median pain scores during hysteroscope insertion, measured on a Visual Analog Scale (VAS), were 1 (interquartile range (IQR) 0-0), 2 (0-4) and 1 (0-1) in the nifedipine, naproxen and placebo group, respectively (P,14). The median VAS scores during hysteroscopy were 5 (IQR 2-7), 5 (4-8) and 5 (3-7) in the nifedipine, naproxen and placebo group, respectively (P,73). The median VAS scores immediately after hysteroscopy were 2 (IQR 0-4), 3 (0-6) and 3 (1-5) in the nifedipine, naproxen and placebo group, respectively (P,40). The median VAS scores 30 minutes after hysteroscopy were 1 (IQR 0-2), 1 (0-1) and 1 (0-2) in the nifedipine, naproxen and placebo group, respectively (P,63). Hysteroscope insertion failed in 1 case (naproxen group) because of cervica`l stenosis (P,32). Flushes, fatigue and vertigo, 30 minutes after the procedure, were significantly more prevalent in the nifedipine group compared to the naproxen (p < .001, p,03, p,03, respectively) and the placebo group (p < .001, p,01, p,01, respectively). Palpitations occurred only in the nifedipine group (p < .001). The day after the procedure, the headache was most prevalent in the nifedipine group compared to the naproxen group (p,001) and the placebo group (p,001).
In our pilot study, pain relief and success rates for office diagnostic hysteroscopy were not significantly different between nifedipine, naproxen, and placebo. Nifedipine was associated with more, albeit tolerable, side-effects.
比较硝苯地平、萘普生或安慰剂在诊断性宫腔镜检查中的止痛效果。
双盲、随机对照初步研究。
大学医院。
计划行门诊诊断性宫腔镜检查的女性(n=60)。
女性在宫腔镜检查前 30 至 60 分钟服用硝苯地平(2 片 10mg)、萘普生(2 片 250mg)或安慰剂(2 片 500mg 乳糖)。
60 名患者入组本研究(硝苯地平组 21 例,萘普生组 19 例,安慰剂组 20 例)。视觉模拟评分(VAS)测量的宫腔镜插入时的中位数疼痛评分分别为硝苯地平组 1(四分位距(IQR)0-0)、萘普生组 2(0-4)和安慰剂组 1(0-1)(P,14)。宫腔镜检查时的中位数 VAS 评分分别为硝苯地平组 5(IQR 2-7)、萘普生组 5(4-8)和安慰剂组 5(3-7)(P,73)。宫腔镜检查后立即的中位数 VAS 评分分别为硝苯地平组 2(IQR 0-4)、萘普生组 3(0-6)和安慰剂组 3(1-5)(P,40)。宫腔镜检查后 30 分钟的中位数 VAS 评分分别为硝苯地平组 1(IQR 0-2)、萘普生组 1(0-1)和安慰剂组 1(0-2)(P,63)。1 例(萘普生组)因宫颈狭窄导致宫腔镜插入失败(P,32)。与萘普生组(p<.001,p<.03,p<.03)和安慰剂组(p<.001,p<.01,p<.01)相比,硝苯地平组术后 30 分钟时潮红、疲劳和眩晕更为常见。心动过速仅发生在硝苯地平组(p<.001)。术后第 1 天,与萘普生组(p<.001)和安慰剂组(p<.001)相比,硝苯地平组头痛发生率最高。
在我们的初步研究中,硝苯地平、萘普生和安慰剂在门诊诊断性宫腔镜检查中的止痛效果和成功率无显著差异。硝苯地平虽有副作用,但可耐受。